25 August 2016Big Pharma

Video interview: Hogan Lovells discusses implications of Brexit on SPCs

In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates (SPCs).

Bennett also covers the challenges facing SPC owners, how they should be tackled, and what SPC owners can do to minimise any negative impact of Brexit.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More on this story

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.

More features

US agency warns 10 pharma companies of filing ‘bogus’ patents

BioNTech’s patent juggling act: protecting innovation amid IP challenges

USPTO veteran joins Finnegan as of counsel in Washington, DC

CureVac and Acuitas wind up COVID-19 vaccine dispute

Amgen and Sandoz settle dispute over blockbuster bone condition drugs

GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents

GSK settles HIV drug licensing dispute

Meeting the cell and gene therapy scale-up challenge